These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 21707531)

  • 41. Inhibitory effect on cerebral inflammatory agents that accompany traumatic brain injury in a rat model: a potential neuroprotective mechanism of recombinant human erythropoietin (rhEPO).
    Chen G; Shi JX; Hang CH; Xie W; Liu J; Liu X
    Neurosci Lett; 2007 Oct; 425(3):177-82. PubMed ID: 17825990
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Erythropoietin exerts neuroprotection after acute spinal cord injury in rats: effect on lipid peroxidation and early ultrastructural findings.
    Kaptanoglu E; Solaroglu I; Okutan O; Surucu HS; Akbiyik F; Beskonakli E
    Neurosurg Rev; 2004 Apr; 27(2):113-20. PubMed ID: 12920606
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The nasal route as a potential pathway for delivery of erythropoietin in the treatment of acute ischemic stroke in humans.
    Garcia-Rodriguez JC; Sosa-Teste I
    ScientificWorldJournal; 2009 Sep; 9():970-81. PubMed ID: 19768354
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Carbamylated erythropoietin reduces radiosurgically-induced brain injury.
    Erbayraktar S; de Lanerolle N; de Lotbinière A; Knisely JP; Erbayraktar Z; Yilmaz O; Cerami A; Coleman TR; Brines M
    Mol Med; 2006; 12(4-6):74-80. PubMed ID: 16953562
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Carbamylated Erythropoietin Outperforms Erythropoietin in the Treatment of AKI-on-CKD and Other AKI Models.
    Tögel FE; Ahlstrom JD; Yang Y; Hu Z; Zhang P; Westenfelder C
    J Am Soc Nephrol; 2016 Nov; 27(11):3394-3404. PubMed ID: 26984884
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neuroprotective effects of erythropoietin pretreatment in a rodent model of transient middle cerebral artery occlusion.
    Ratilal BO; Arroja MM; Rocha JP; Fernandes AM; Barateiro AP; Brites DM; Pinto RM; Sepodes BM; Mota-Filipe HD
    J Neurosurg; 2014 Jul; 121(1):55-62. PubMed ID: 24702327
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pretreatment with erythropoietin attenuates the neurological injury after spinal cord ischemia.
    Hwang J; Huh J; Kim J; Jeon Y; Cho S; Han S
    Spinal Cord; 2012 Mar; 50(3):208-12. PubMed ID: 22124347
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The efficacy of erythropoietin on acute spinal cord injury. An experimental study on a rat model.
    Kontogeorgakos VA; Voulgaris S; Korompilias AV; Vekris M; Polyzoidis KS; Bourantas K; Beris AE
    Arch Orthop Trauma Surg; 2009 Feb; 129(2):189-94. PubMed ID: 18309506
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Carbamylated erythropoietin to treat neuronal injury: new development strategies.
    Lapchak PA
    Expert Opin Investig Drugs; 2008 Aug; 17(8):1175-86. PubMed ID: 18616414
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Erythropoietin signaling increases neurogenesis and oligodendrogenesis of endogenous neural stem cells following spinal cord injury both in vivo and in vitro.
    Zhang H; Fang X; Huang D; Luo Q; Zheng M; Wang K; Cao L; Yin Z
    Mol Med Rep; 2018 Jan; 17(1):264-272. PubMed ID: 29115443
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment of traumatic brain injury in rats with erythropoietin and carbamylated erythropoietin.
    Mahmood A; Lu D; Qu C; Goussev A; Zhang ZG; Lu C; Chopp M
    J Neurosurg; 2007 Aug; 107(2):392-7. PubMed ID: 17695395
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tolerability and efficacy of erythropoietin (EPO) treatment in traumatic spinal cord injury: a preliminary randomized comparative trial vs. methylprednisolone (MP).
    Costa DD; Beghi E; Carignano P; Pagliacci C; Faccioli F; Pupillo E; Messina P; Gorio A; Redaelli T
    Neurol Sci; 2015 Sep; 36(9):1567-74. PubMed ID: 25820146
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Differential neuroprotective properties of endogenous and exogenous erythropoietin in a mouse model of traumatic brain injury.
    Shein NA; Grigoriadis N; Alexandrovich AG; Simeonidou C; Spandou E; Tsenter J; Yatsiv I; Horowitz M; Shohami E
    J Neurotrauma; 2008 Feb; 25(2):112-23. PubMed ID: 18260794
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Investigation of efficacy of treatment in spinal cord injury: Erythropoietin versus methylprednisolone.
    Ozkunt O; Sariyilmaz K; Gemalmaz HC; Gürgen SG; Yener U; Dikici F
    J Orthop Surg (Hong Kong); 2017; 25(3):2309499017739481. PubMed ID: 29121822
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of tacrolimus and erythropoietin in experimental spinal cord lesion in rats: functional and histological evaluation.
    de Mesquita Coutinho PR; Cristante AF; de Barros Filho TE; Ferreira R; Dos Santos GB
    Spinal Cord; 2016 Jun; 54(6):439-44. PubMed ID: 26481712
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Reduced functional deficits, neuroinflammation, and secondary tissue damage after treatment of stroke by nonerythropoietic erythropoietin derivatives.
    Villa P; van Beek J; Larsen AK; Gerwien J; Christensen S; Cerami A; Brines M; Leist M; Ghezzi P; Torup L
    J Cereb Blood Flow Metab; 2007 Mar; 27(3):552-63. PubMed ID: 16835629
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The effects of systemically administered methylprednisolone and recombinant human erythropoietin after acute spinal cord compressive injury in rats.
    Cetin A; Nas K; Büyükbayram H; Ceviz A; Olmez G
    Eur Spine J; 2006 Oct; 15(10):1539-44. PubMed ID: 16547753
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Erythropoietin-mediated protection in kidney transplantation: nonerythropoietic EPO derivatives improve function without increasing risk of cardiovascular events.
    van Rijt WG; van Goor H; Ploeg RJ; Leuvenink HG
    Transpl Int; 2014 Mar; 27(3):241-8. PubMed ID: 23964738
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sub-acute systemic erythropoietin administration reduces ischemic brain injury in an age-dependent manner.
    Thériault P; Le Béhot A; ElAli A; Rivest S
    Oncotarget; 2016 Jun; 7(24):35552-35561. PubMed ID: 27248662
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The analytical approach for detection of carbamylated erythropoietin for doping control purposes.
    Kaliszewski P; Siek P; Zalewska Z; Michalak D; Kwiatkowska D
    Drug Test Anal; 2020 Nov; 12(11-12):1599-1604. PubMed ID: 33119952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.